The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism

American Journal of Physiology - Renal Physiology

Volumn 288, Issue 2 57-2, 2005, Pages

  Rodriguez, Mariano ^a   Nemeth, Edward ^b,c   Martin, David ^c  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b The Research Doctor   (Canada)

^c AMGEN INC   (United States)

Author keywords

Calcimimetics; Chronic kidney disease; Phosphorus

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG EFFICACY; HORMONE SYNTHESIS; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FUNCTION; MINERAL METABOLISM; PARATHYROID CELL; PARATHYROID GLAND; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECONDARY HYPERPARATHYROIDISM;

EID: 12144285037     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00302.2004     Document Type: Article

References (147)

1. Akizawa T and Fukagawa M. Modulation of parathyroid cell function by calcium ion in health and uremia. Am J Med Sci 317: 358-362, 1999.
2. Almaden Y, Canalejo A, Ballesteros E, Anon G, Canadillas S, and Rodriguez M. Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of extracellular phosphate. J Am Soc Nephrol 13: 693-698, 2002.
3. Almaden Y, Canalejo A, Ballesteros E, Anon G, and Rodriguez M. Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J Am Soc Nephrol 11: 1712-1718, 2002.
4. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, and Rodriguez M. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 11: 970-976, 1996.
5. Almaden Y, Felsenfeld AJ, Rodriguez M, Canadillas S, Luque F, Bas A, Bravo J, Torregrosa V, Palma A, Ramos B, Sanchez C, Martin-Malo A, and Canalejo A. Proliferation in hyperplastic human and normal rat parathyroid glands: role of phosphate, calcitriol, and gender. Kidney Int 64: 2311-2317, 2003.
6. Almaden Y, Hernandez A, Torregrosa V, Canalejo A, Sabate L, Fernandez Cruz L, Campistol JM, Torres A, and Rodriguez M. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 9: 1845-1852, 1998.
7. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, and Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95: 2047-2053, 1995.
8. Berdud I, Martin-Malo A, Almaden Y, Tallon S, Concepcion MT, Torres A, Felsenfeld A, Aljama P, and Rodriguez M. Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Nephrol Dial Transplant 11: 1292-1298, 1996.
9. Block G, Klassen PS, Kim J, LaBrecque J, and Danese M. Relationship between serum calcium and mortality risk in hemodialysis patients. Am J Kidney Dis 41: A16, 2003.
10. Block GA, Hulbert S, Levin NW, and Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617, 1998.
11. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, and Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004.
12. 2 action and arachidonic acid metabolism in calcium-mediated parathyroid hormone secretion. Endocrinology 130: 1339-1344, 1992.
13. Bover J, Jara A, Trinidad P, Rodriguez M, and Felsenfeld AJ. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus. Bone 25: 279-285, 1999.
14. Bover J, Jara A, Trinidad P, Rodriguez M, Martin-Malo A, and Felsenfeld AJ. The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia. Kidney Int 46: 310-317, 1994.
15. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Dis 1: 307-315, 2000.
16. 2+-sensing receptor from bovine parathyroid. Nature 366: 575-580, 1993.
17. Brown AJ, Ritter CS, Finch JL, and Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 55: 1284-1292, 1999.
18. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, and Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol Renal Fluid Electrolyte Physiol 270: F454-F460, 1996.
19. Canaff L and Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 277: 30337-30350, 2002.
20. Canalejo A, Canadillas S, Ballesteros E, Rodriguez M, and Almaden Y. Importance of arachidonic acid as a mediator of parathyroid gland response. Kidney Int Suppl 85: S10-S13, 2003.
21. Cannata-Andia J, Fernandez-Martin JL, and Diaz-Corte C. Applying the K/DOQI guidelines cut-off levels to the dialysis population: how far are we from the target (Abstract)? J Am Soc Nephrol 14: 474A, 2003.
22. Carling T, Rastad J, Szabo E, Westin G, and Akerstrom G. Reduced parathyroid vitamin D receptor messenger ribonucleic acid levels in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 85: 2000-2003, 2000.
23. De Francisco AL, Cobo MA, Setien MA, Rodrigo E, Fresnedo GF, Unzueta MT, Amado JA, Ruiz JC, Arias M, and Rodriguez M. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int 54: 2140-2145, 1998.
24. Delmez JA, Kelber J, Norwood KY, Giles KS, and Slatopolsky E. A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. Clin Nephrol 54: 301-308, 2000.
25. Delmez JA and Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19: 303-317, 1992.
26. Denda M, Finch J, and Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28: 596-602, 1996.
27. Drueke TB. Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Pediatr Nephrol 10: 348-350, 1996.
28. Drüeke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 48: 259-272, 1995.
29. Drüeke TB, Corrèze MC, Gogusev J, Sarfati E, and Bourdeau A. Effect of phosphate on PTH secretion by human parathyroid cells in culture. Nephrol Dial Transplant 12: A37, 1997.
30. D'Souza-Li L, Yang B, Canaff L, Bai M, Hanley DA, Bastepe M, Salisbury SR, Brown EM, Cole DE, and Hendy GN. Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. J Clin Endocrinol Metab 87: 1309-1318, 2002.
31. Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ, Morrissey J, and Slatopolsky E. p21 (WAF1) and transforming growth factor-α mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 59: 855-865, 2001.
32. Eknoyan G, Levin A, and Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1-201, 2003.
33. Estepa JC, Aguilera-Tejero E, Lopez I, Almaden Y, Rodriguez M, and Felsenfeld AJ. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res 14: 1848-1854, 1999.
34. Felsenfeld AJ, Jara A, Pahl M, Bover J, and Rodriguez M. Differences in the dynamics of parathyroid hormone secretion in hemodialysis patients with marked secondary hyperparathyroidism. J Am Soc Nephrol 6: 1371-1378, 1995.
35. Felsenfeld AJ and Rodriguez M. Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 10: 878-890, 1999.
36. Fox J, Lowe SH, Petty BA, and Nemeth EF. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290: 473-479, 1999.
37. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436-1443, 1993.
38. Galceran T, Martin KJ, Morrissey JJ, and Slatopolsky E. Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Kidney Int 32: 801-807, 1987.
39. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001.
40. Garfia B, Canadillas S, Canalejo A, Luque F, Siendones E, Quesada M, Almaden Y, Aguilera-Tejero E, and Rodriguez M. Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Am Soc Nephrol 13: 2945-2952, 2002.
41. Garrett JE, Steffey ME, and Nemeth EF. The calcium receptor agonist NPS R-568 suppresses PTH mRNA levels in cultured bovine parathyroid cells (Abstract). J Bone Miner Res 10: S387, 1995.
42. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, and Drueke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51: 328-336, 1997.
43. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, and Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58: 436-445, 2000.
44. Goodman WG and Turner SA. Future role of calcimimetics in end-stage renal disease. Adv Ren Replace Ther 9: 200-208, 2002.
45. Goodman WG, Veldhuis JD, Belin TR, Van Herle AJ, Juppner H, and Salusky IB. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 83: 2765-2772, 1998.
46. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53: 1083-1088, 1998.
47. 2+ receptor/metabotropic glutamate chimeric receptors. Endocrinology 141: 4156-4163, 2000.
48. Hayakawa Y, Tanaka Y, Funahashi H, Imai T, Matsuura N, Oiwa M, Kikumori T, Mase T, Tominaga Y, and Nakao A. Hyperphosphatemia accelerates parathyroid cell proliferation and parathyroid hormone secretion in severe secondary parathyroid hyperplasia. Endocr J 46: 681-686, 1999.
49. Hendy GN, Stotland MA, Grunbaum D, Fraher LJ, Loveridge N, and Goltzman D. Characteristics of secondary hyperparathyroidism in vitamin D-deficient dogs. Am J Physiol Endocrinol Metab 256: E765-E772, 1989.
50. Hernandez A, Concepcion MT, Rodriguez M, Salido E, and Torres A. High phosphorus diet increases preproPTH mRNA independent of calcium and calcitriol in normal rats. Kidney Int 50: 1872-1878, 1996.
51. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, and Seidman CE. A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 11: 389-394, 1995.
52. Hruska KA and Teitelbaum SL. Renal osteodystrophy. N Engl J Med 333: 166-174, 1995.
53. Hsu CH, Patel SR, and Vanholder R. Mechanism of decreased intestinal calcitriol receptor concentration in renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 264: F662-F669, 1993.
54. Hsu CH, Patel SR, and Young EW. Mechanism of decreased calcitriol degradation in renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 262: F192-F198, 1992.
55. Hsu CH, Patel SR, Young EW, and Vanholder R. Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol Renal Fluid Electrolyte Physiol 260: F596-F601, 1991.
56. 3 and diltiazem on tissue calcium in uremic rat. Ren Fail 17: 651-657, 1995.
57. 2+-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Am J Hum Genet 56: 880-886, 1995.
58. Johnson CA, McCarthy J, Bailie GR, Deane J, and Smith S. Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 39: 1270-1277, 2002.
59. 3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98: 1302-1306, 1998.
60. Josifovska T, Nonoguchi H, Machida K, and Tomita K. Mechanisms of down-regulation of the renal parathyroid hormone receptor in rats with chronic renal failure. Nephron Exp Nephrol 93: e141-e149, 2003.
61. 2+-sensor of human parathyroid cells. Biochem Biophys Res Commun 143: 570-574, 1987.
62. 2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J Bone Miner Res 12: 715-725, 1997.
63. Kifor O, MacLeod RJ, Diaz R, Bai M, Yamaguchi T, Yao T, Kifor I, and Brown EM. Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells. Am J Physiol Renal Physiol 280: F291-F302, 2001.
64. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81: 1598-1606, 1996.
65. Kilav R, Silver J, and Naveh-Many T. A conserved cis-acting element in the parathyroid hormone 3′-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J Biol Chem 276: 8727-8733, 2001.
66. Kilav R, Silver J, and Naveh-Many T. Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest 96: 327-333, 1995.
67. Krause MW and Hedinger CE. Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum Pathol 16: 772-784, 1985.
68. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, and Martin KJ. The calcimimetic AMG073 reduces parathyroid hormone and calcium X phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248-254, 2003.
69. Llach F and Massry SG. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61: 601-606, 1985.
70. Malberti F, Farina M, and Imbasciati E. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 14: 2398-2406, 1999.
71. 3 but not cinacalcet HCl treatment mediates aortic mineralization in a rat model of secondary hyperparathyroidism (Abstract). J Am Soc Nephrol 14: 693A, 2003.
72. Martin D, Miller G, Colloton M, Shatzen E, and Lacey D. Cinacalcet HCl decreases parathyroid hyperplasia in a rodent model of chronic renal insufficiency (CRI) (Abstract). J Am Soc Nephrol 14: 462A, 2003.
73. Martin LN, Kayath MJ, Vieira JG, and Nose A. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis. Histopathology 33: 46-51, 1998.
74. Martinez I, Saracho R, Montenegro J, and Llach F. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29: 496-502, 1997.
75. Massry SG and Coburn JW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42, Suppl 3: S1-S201, 2003.
76. Mayer GP and Hurst JG. Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. Endocrinology 102: 1036-1042, 1978.
77. Miyamoto K, Tatsumi S, Morita K, and Takeda E. Does the parathyroid "see" phosphate? Nephrol Dial Transplant 13: 2727-2729, 1998.
78. Moallem E, Kilav R, Silver J, and Naveh-Many T. RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273: 5253-5259, 1998.
79. National Institutes of Health. USRDS 2003. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
80. Naveh-Many T, Rahamimov R, Livni N, and Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96: 1786-1793, 1995.
81. Naveh-Many T and Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 86: 1313-1319, 1990.
82. Nemeth EF. Calcimimetic and calcilytic drugs: just for parathyroid cells? Cell Calcium 35: 283-289, 2004.
83. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 8: 2077-2087, 2002.
84. Nemeth EF and Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 10: 66-71, 1999.
85. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, and Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627-635, 2004.
86. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, and Balandrin MF. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95: 4040-4045, 1998.
87. Nielsen PK, Feldt-Rasmussen U, and Olgaard K. A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant 11: 1762-1768, 1996.
88. 2+-sensing function of parathyroid cells in vitro and in hyperparathyroidism. Biochim Biophys Acta 968: 253-260, 1988.
89. Ogata H, Ritz E, Odoni G, Amann K, and Orth SR. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14: 959-967, 2003.
90. Owda AK, Mousa D, Abdallah AH, Hawas FA, Al-Harbi W, Fedail H, At-Shoail G, Al-Sulaiman MH, and Al-Khader AA. Long-term intravenous calcitriol in secondary hyperparathyroidism: the role of technetium-99m-MIBI scintigraphy in predicting the response to treatment. Ren Fail 24: 165-173, 2002.
91. Pahl M, Jara A, Bover J, Rodriguez M, and Felsenfeld AJ. The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients. Kidney Int 49: 226-231, 1996.
92. Parfitt AM. In: Bilezikian JP, Marcus R, and Levine M (Editors). Parathyroid growth. In: The Parathyroids Basic and Clinical Concepts (2nd ed.). San Diego, CA: Academic, 2001, p. 293-329.
93. Patel SR, Ke HQ, Vanholder R, and Hsu CH. Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. Kidney Int 46: 129-133, 1994.
94. Pearce SH, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, Heath DA, Hughes IA, Paterson CR, Whyte MP, and Thakker RV. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 96: 2683-2692, 1995.
95. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, and Puschett JB. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876-881, 1988.
96. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75: 1297-1303, 1993.
97. Portale AA, Halloran BP, and Morris RC Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 83: 1494-1499, 1989.
98. Qi Q, Monier-Faugere MC, Geng Z, and Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26: 622-631, 1995.
99. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, and Bushinsky DA. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14: 1710-1721, 2003.
100. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, and Lobaugh BA. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45: 1710-1721, 1994.
101. Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV, and Salusky IB. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 76: 1489-1494, 1993.
102. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, and Ribeiro F. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037-2040, 1998.
103. Ritter CS, Finch JL, Slatopolsky EA, and Brown AJ. Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor. Kidney Int 60: 1737-1744, 2001.
104. Ritz E, Kuster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, and Heidland A. Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 10: 2228-2234, 1995.
105. 3 in response to parathyroid hormone in patients with incipient renal failure. Nephron 57: 314-318, 1991.
106. Rodriguez M. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int 61: S155-S160, 2002.
107. Rodriguez M, Almaden Y, Hernandez A, and Torres A. Effect of phosphate on the parathyroid gland: direct and indirect? Curr Opin Nephrol Hypertens 5: 321-328, 1996.
108. Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Jimenez A, Torres A, and Felsenfeld AJ. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int 56: 306-317, 1999.
109. Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Rodriguez AP, and Felsenfeld AJ. Evidence for both abnormal set point of PTH stimulation by calcium and adaptation to serum calcium in hemodialysis patients with hyperparathyroidism. J Bone Miner Res 12: 347-355, 1997.
110. Rodriguez M, Felsenfeld AJ, and Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney Int 40: 1063-1068, 1991.
111. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, and Llach F. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2: 1014-1020, 1991.
112. Rodriguez M, Martin-Malo A, Martinez ME, Torres A, Felsenfeld AJ, and Llach F. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int 40: 1055-1062, 1991.
113. Santamaria R, Almaden Y, Felsenfeld A, Martin-Malo A, Gao P, Cantor T, Aljama P, and Rodriguez M. Dynamics of PTH secretion in hemodialysis patients as determined by the intact and whole PTH assays. Kidney Int 64: 1867-1873, 2003.
114. Sela-Brown A, Russell J, Koszewski NJ, Michalak M, Naveh-Many T, and Silver J. Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcaemic rats. Mol Endocrinol 12: 1193-1200, 1998.
115. Silver J. Pathogenesis of parathyroid dysfunction in end-stage renal disease. Adv Ren Replace Ther 9: 159-167, 2002.
116. Silver J, Sela SB, and Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 6: 321-326, 1997.
117. Slatopolsky E and Delmez JA. Pathogenesis of secondary hyperparathyroidism. Miner Electrolyte Metab 21: 91-96, 1995.
118. Slatopolsky E, Dusso A, and Brown AJ. The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am J Med Sci 317: 370-376, 1999.
119. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, and Dusso A. A novel mechanism for skeletal resistance in uremia. Kidney Int 58: 753-761, 2000.
120. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, and Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97: 2534-2540, 1996.
121. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, and Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-2143, 1984.
122. Somerville PJ and Kaye M. Action of phosphorus on calcium release in isolated perfused rat tails. Kidney Int 22: 348-354, 1982.
123. Somerville PJ and Kaye M. Evidence that resistance to the calcemic action of parathyroid hormone in rats with acute uremia is caused by phosphate retention. Kidney Int 16: 552-560, 1979.
124. Somerville PJ and Kaye M. Resistance to parathyroid hormone in renal failure: role of vitamin D metabolites. Kidney Int 14: 245-254, 1978.
125. Stengel B, Billon S, Van Dijk PC, Jager KJ, Dekker FW, Simpson K, and Briggs JD. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 18: 1824-1833, 2003.
126. St. John A, Thomas MB, Davies CP, Mullan B, Dick I, Hutchison B, van der Schaff A, and Prince RL. Determinants of intact parathyroid hormone and free 1,25-dihydroxyvitamin D levels in mild and moderate renal failure. Nephron 61: 422-427, 1992.
127. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35: 1049-1056, 1989.
128. Takahashi H, Shimazawa E, Horiuchi N, Suda T, Yamashita K, and Ogata E. An estimation of the parathyroid hormone secretion rate in vitamin D deficient rats. Horm Metab Res 10: 161-167, 1978.
129. Tallon S, Berdud I, Hernandez A, Concepcion MT, Almaden Y, Torres A, Martin-Malo A, Felsenfeld AJ, Aljama P, and Rodriguez M. Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats. Kidney Int 49: 1441-1446, 1996.
130. Tatsumi S, Segawa H, Morita K, Haga H, Kouda T, Yamamoto H, Inoue Y, Nii T, Katai K, Taketani Y, Miyamoto KI, and Takeda E. Molecular cloning and hormonal regulation of PiT-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 139: 1692-1699, 1998.
131. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, and Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int 62: 1196-1207, 2002.
132. Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y, and Takagi H. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 20: 744-750, 1996.
133. Tominaga Y, Sato K, Tanaka Y, Numano M, Uchida K, and Takagi H. Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure. Clin Nephrol 44, Suppl 1: S42-S47, 1995.
134. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, and Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13: 78-86, 1997.
135. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, de Bonis E, Darias E, Gonzalez-Posada JM, Losada M, Rufino M, Felsenfeld AJ, and Rodríguez M. Bone disease in predialysis haemodialysis, and CAPD patients; evidence of a better bone response to PTH. Kidney Int 47: 1434-1442, 1995.
136. Urena P, Kubrusly M, Mannstadt M, Hruby M, Trinh MM, Silve C, Lacour B, Abou-Samra AB, Segre GV, and Drueke T. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 45: 605-611, 1994.
137. Wada M, Furuya Y, Kobayashi N, Kobayashi N, Miyata S, Ishii H, and Nagano N. The calcimimetic compound AMG 073 (cinacalcet HCl) ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J Am Soc Nephrol 14: 48A (abstract SU-FC218), 2003.
138. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, and Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100: 2977-2983, 1997.
139. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, and Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448-453, 1998.
140. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, and Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidisrn. Kidney Int 57: 50-58, 2000.
141. Wang Q, Palnitkar S, and Parfitt AM. Parathyroid cell proliferation in the rat: effect of age and of phosphate administration and recovery. Endocrinology 137: 4558-4562, 1996.
142. Wang Q, Paloyan E, and Parfitt AM. Phosphate administration increases both size and number of parathyroid cells in adult rats. Calcif Tissue Int 58: 40-44, 1996.
143. Wang X, Sun B, Zhou F, Hu J, Yu X, and Peng T. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients. Chin Med J (Engl) 114: 410-414, 2001.
144. Yamamoto M, Igarashi T, Muramatsu M, Fukagawa M, Motokura T, and Ogata E. Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J Clin Invest 83: 1053-1056, 1989.
145. Yano S, Sugimoto T, Tsukamoto T, Tsukamoto T, Hattori T, Hattori S, and Chihara K. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidisrn. Kidney Int 58: 1980-1986, 2000.
146. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, and Kurokawa K. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 70: 242-248, 1995.
147. Young E, Satayathum S, Pisoni R, Locatelli F, Canaud B, Kurokawa K, Akiba T, Saito A, Mapes D, and Port F. Prevalence of values on mineral metabolism being made outside the targets from the proposed new draft NKF-K/DOQI and European Best Practice Guidelines in countries of the Dialysis Outcomes and Practice Patterns Study (DOPPS) (Abstract). Nephrol Dial Transplant 18, Suppl 4: 677, 2003.